Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Morillas

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Gastroenterologia Y Hepatologia|June 2, 1998
[Hepatorenal syndrome]R M Morillas, J Santos, M Hombrados, et al.
Journal of Viral Hepatitis|May 22, 2010
A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatmentB Soldevila, N Alonso, M J Martínez-Arconada, et al.
Journal of Viral Hepatitis|August 20, 2005
Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*V González, E Padilla, M Diago, et al.
Hepatology (Baltimore, Md.)|December 1, 1994
Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effectsR M Morillas, R Planas, E Cabré, et al.
Gastroenterologia Y Hepatologia|May 7, 2003
[Presinusoidal portal hypertension due to portal thrombosis in a patient with Alagille's syndrome]V Lorenzo-Zúñiga, R M Morillas, R Planas, et al.
Journal of Viral Hepatitis|December 16, 2016
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infectionC Perelló, J A Carrión, B Ruiz-Antorán, et al.
Alimentary Pharmacology & Therapeutics|May 1, 2024
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practiceE Gómez, J L Montero, E Molina, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Gastroenterologia Y Hepatologia|June 2, 1998
[Hepatorenal syndrome]R M Morillas, J Santos, M Hombrados, et al.
Journal of Viral Hepatitis|May 22, 2010
A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatmentB Soldevila, N Alonso, M J Martínez-Arconada, et al.
Journal of Viral Hepatitis|August 20, 2005
Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*V González, E Padilla, M Diago, et al.
Hepatology (Baltimore, Md.)|December 1, 1994
Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effectsR M Morillas, R Planas, E Cabré, et al.
Gastroenterologia Y Hepatologia|May 7, 2003
[Presinusoidal portal hypertension due to portal thrombosis in a patient with Alagille's syndrome]V Lorenzo-Zúñiga, R M Morillas, R Planas, et al.
Journal of Viral Hepatitis|December 16, 2016
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infectionC Perelló, J A Carrión, B Ruiz-Antorán, et al.
Alimentary Pharmacology & Therapeutics|May 1, 2024
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practiceE Gómez, J L Montero, E Molina, et al.
Pageof 1